Enter Note Done
Go to previous page in this tab
Session
  • Presentation | SOA - Update on MASLD Therapies Pipeline
  • AASLD
  • 723: ONCE-MONTHLY EFIMOSFERMIN ALFA (BOS-580) IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS WITH F2/F3 FIBROSIS: RESULTS FROM A 24 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL
  • Session Number: 0005
    Set Timezone

Presentation ID: 723

4249840

Society
Main Session